Article
AstraZeneca says Lynparza gets EU nod to treat early-stage breast cancer
Rating:
0.0
Views:
45
Likes:
1
Library:
1
AstraZeneca said on Thursday its drug Lynparza, developed with U.S.-based Merck & Co , was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value